MAP2K1 and neoplasm: In summary, our study suggests that acetylshikonin can inhibit the growth of colorectal cancer tumours, in vitro and in vivo, by suppressing TOPK signalling through its direct targeting of TOPK, without modulation of MEK1 activity.